A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia
Nutrients · 2023
DOI: 10.3390/nu15030492 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Yuqing Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Uric Acid, Dyslipidemias. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose–response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo (n = 43) and resveratrol treatment groups of 100 mg/d (n = 41), 300 mg/d (n = 43), and 600 mg/d (n = 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (−23.60 ± 61.53 μmol/L, p < 0.05) and 600 mg/d resveratrol groups (−24.37 ± 64.24 μmol/L, p < 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (−0.09 ± 0.29 U/mL, p < 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose–response relationship (p for trend,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
- Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, China.
- Guangdong Engineering Technology Center of Nutrition Transformation, Guangzhou 510080, China.
- Department of Nutrition, School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.
ORCID-Profile: Yan Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Zeng, Y., Pan, Z., Jin, Y., Li, Q., Pang, J., Wang, X., Chen, Y., Yang, Y., & Ling, W. (2023). A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia. Nutrients. https://doi.org/10.3390/nu15030492
Vancouver
Zhou Y, Zeng Y, Pan Z, Jin Y, Li Q, Pang J, et al. A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia. Nutrients. 2023. doi:10.3390/nu15030492
BibTeX
@article{Zhou2023,
author = {Zhou, Yuqing and Zeng, Yupeng and Pan, Zhijun and Jin, Yufeng and Li, Qing and Pang, Juan and Wang, Xin and Chen, Yu and Yang, Yan and Ling, Wenhua},
title = {A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15030492}
}
EUVIMED